TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2529731
Drug: Meperidine (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (0.35 mg/kg)
Study: 2529731
Drug: Morphine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.04 mg/kg)
Study: 21813328
Drug: Food supplementation
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplementation rich in arginine (peanuts, equivalent to 1 g of arginine/day)
Study: 19380449
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg/day) plus Letrozole (2.5 mg/day)
Study: 19380449
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Letrozole (2.5 mg/day)
Study: 17050503
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lisinopril plus 50 mg losartan
Study: 3534629
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg b.i.d. for 4 weeks
Study: 27399197
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg bd
Study: 20964867
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with daily 1-hydroxycholecalciferol (Alfacalcidol; 1 μg) and calcium supplement
Study: 12584032
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day; n = 20)
Study: 12584032
Drug: Transdermal 17beta
Normalized name: 17beta oestradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta estradiol (50 microg/day; n = 39)
Study: 9301412
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 14 g inulin added to a low-fat spread
Study: 3521207
Drug: Low-dose streptokinase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose streptokinase (SK) combined with low-dose heparin
Study: 3521207
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Heparin and Low-dose SK)
Study: 29797503
Drug: Fructose (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (any dose)
Study: 29797503
Drug: Allulose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allulose (5 g, 10 g, pooled doses)
Study: 24438561
Drug: Light Force
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light Force (40 g)
Study: 24438561
Drug: Heavy Force
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy Force (120 g)
Study: 22394412
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment (group I)
Study: 22394412
Drug: Diuretic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic and vasodilator treatment (group II)
Study: 18243665
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of interferon-gamma (rIFN-gamma or nIFN-gamma) and narrowband UVB (NB-UVB)
Study: 18243665
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB (NB-UVB) monotherapy
Study: 12964857
Drug: HBO2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 therapy (5 sessions of breathing 95% oxygen at 2.5 atm abs for 100 min)
Study: 8871872
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy at a dose of 5 MU subcutaneously three times weekly for 6 months
Study: 1518433
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous (SC) octreotide infusion
Study: 1518433
Drug: Octreotide injection
Normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide injection
Study: 6378615
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg BID, dose increased biweekly)
Study: 30950431
Drug: Anti-HCV antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-HCV antibody testing
Study: 30950431
Drug: Adjusted odds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted odds of testing positive for anti-HCV antibody
Study: 19606675
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration for 3 months in patients with functional dyspepsia and H. pylori infection (n=30)
Study: 19606675
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration for 3 months in patients with functional dyspepsia without H. pylori infection (n=30)
Study: 8869897
Drug: UV‐A1 irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV‐A1 irradiation (twice- and once-weekly)
Study: 1740065
Drug: Outpatient bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient bowel preparation
Study: 1740065
Drug: Inpatient bowel
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient bowel preparation
Study: 6655288
Drug: Dengue 2
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue 2 vaccine (0.5 ml, doses of 10(1.8)‐10(5.5) plaque-forming units)
Study: 31185041
Drug: 0.12% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% betamethasone valerate ointment applied twice a day after washing or bathing by parents
Study: 25569028
Drug: High-dose barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose barium impaction therapy
Study: 19822100
Drug: Oral hyposensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hyposensitization therapy with low doses of nickel
Study: 16421461
Drug: Amisulpride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400 mg/day up-titrated from 100 mg/day over 1 week)
Study: 16791717
Drug: Pharmacotherapy follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy follow-up program
Study: 1725028
Drug: Ramipril (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5, 5, or 10 mg once daily)
Study: 1725028
Drug: Enalapril (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5, 10, or 20 mg once daily)
Study: 27266883
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping added to physical therapy (exercise and manual therapy)
Study: 20926996
Drug: Tasocitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasocitinib (15 mg or 30 mg twice daily)
Study: 18414066
Drug: High salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: High salt diet (3.86 g, 168 mmol/24 hours sodium)
Study: 18414066
Drug: Low salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low salt diet (1.3 g, 56 mmol/24 hours sodium)
Study: 12459399
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) daily
Study: 1760824
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 2 x 40 mg/day
Study: 1760824
Drug: Atenolol (AT)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (AT) 100 mg/day
Study: 1760824
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of IS-5-MN and AT
Study: 31767518
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg at Weeks 0, 2, 4, and 6, followed by placebo at Week 8, alirocumab at Week 10, placebo at Weeks 12 and 14.
Study: 31767518
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg.
Study: 31767518
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg and placebo.
Study: 29130954
Drug: Tolvaptan (≤15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (≤15 mg/day)
Study: 29130954
Drug: Increased furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased furosemide (≤40 mg/day)
Study: 26401089
Drug: Moxifloxacin-based sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin-based sequential therapy (MBST)
Study: 21928714
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream of Calendula officinalis extract
Study: 19720909
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m(2) over 24 hours plus Cis 50 mg/m(2) day 2 every 3 weeks (PC)
Study: 19720909
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m(2) days 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (VC)
Study: 19720909
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m(2) day 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (GC)
Study: 19720909
Drug: Topotecan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 0.75 mg/m(2) days 1, 2, and 3 plus Cis 50 mg/m(2) day 1 every 3 weeks (TC)
Study: 15364659
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group serving at other S-L sites
Study: 11443156
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day pegvisomant
Study: 8018795
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of GRF (1 micrograms/kg)
Study: 23296629
Drug: soluble human
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: soluble human triggering receptor expressed on myeloid cells-1 (sTREM-1)
Study: 23296629
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PSP (>9 ng/ml) and PCT (>2 ng/ml)
Study: 16289171
Drug: Physiological REM
Normalized name: REM-422
DrugBank: REM-422 (DB19304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological REM sleep augmentation via REM sleep rebound after selective REM sleep deprivation
Study: 16289171
Drug: Pharmacological REM
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological REM sleep augmentation by administering an acetylcholinesterase inhibitor
Study: 12888122
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fludrocortisone p.o.
Study: 12888122
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg aldosterone i.v.
Study: 8689991
Drug: Flumazenil (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for 3 hours)
Study: 8689991
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 hours infusion)
Study: 30551121
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g · kg‐1 BW NaHCO3
Study: 30551121
Drug: 0.1 g
Normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g · kg‐1 BW NaHCO3
Study: 30551121
Drug: Control (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.3 g · kg‐1 BW placebo)
Study: 18033807
Drug: Mild ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild ovarian stimulation/GnRH antagonist co-treatment with single embryo transfer
Study: 18033807
Drug: Standard stimulation/GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard stimulation/GnRH agonist long protocol with transfer of two embryos
Study: 16372578
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg three times daily, orally
Study: 16372578
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment plus TMZ
Study: 12523089
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education (two two-hour group sessions followed by one or two individual sessions administered by a nurse and a physiotherapist)
Study: 9607046
Drug: Triviraten Berna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triviraten Berna Vaccine
Study: 2115892
Drug: Pimozide (2-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (2-18 mg)
Study: 2115892
Drug: Haloperidol (2-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2-15 mg)
Study: 345410
Drug: Metronidazole 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1,000 mg daily for two months
Study: 29394971
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and weight-bearing exercises
Study: 22918094
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 to 0.75 mg/kg)
Study: 22918094
Drug: Oral triclofos
Normalized name: Triclofos
DrugBank: Triclofos (DB06753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral triclofos
Study: 22918094
Drug: Oral zolpidem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zolpidem
Study: 20063224
Drug: IV fluid
Normalized name: IV fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid group (lactated ringers at 250 ml per hour)
Study: 17655695
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) + HBV vaccine (40 mug HBV(vac) after 5 mug/kg GM-CSF injection)
Study: 17655695
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine (40 mug HBV(vac) intramuscularly)
Study: 8819183
Drug: Propranolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (400 mg)
Study: 7295883
Drug: Betamethasone tablet
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone tablet formulation A (2 mg)
Study: 7295883
Drug: Betamethasone tablet
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone tablet formulation B (2 mg)
Study: 7295883
Drug: Betamethasone phosphate
Normalized name: Betamethasone phosphate
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone phosphate solution C (2 mg)
Study: 10445557
Drug: alpha-interferon (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-interferon (5 MU/m2 three times weekly for 6 months)
Study: 8695970
Drug: MFP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP at the dose of 20 mg F-equivalents + 600 mg calcium/day
Study: 8695970
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of oral calcium
Study: 2392980
Drug: Beta 1-selective
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1-selective beta blocker (metoprolol)
Study: 2392980
Drug: Beta 1-nonselective
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1-nonselective beta blocker (propranolol)
Study: 7308268
Drug: muzolimine 240
Normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine 240 mg
Study: 7308268
Drug: furosemide 240
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: furosemide 240 mg
Study: 30117129
Drug: Eldecalcitol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol 0.75 μg
Study: 31087185
Drug: Alfacalcidol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 1.0 μg
Study: 16686722
Drug: Solifenacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (10 mg)
Study: 28050642
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (60 mg)
Study: 22136279
Drug: Chungkookjang (CKJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chungkookjang (CKJ) pills, 35 g per day for 3 months
Study: 22136279
Drug: Placebo pills,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills, 35 g per day for 3 months
Study: 22136279
Drug: Chungkookjang (CKJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chungkookjang (CKJ) pills
Study: 18801775
Drug: Different footwear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different footwear types (air/gel/spring)
Study: 16961791
Drug: Balanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced amino acid condition (L-tryptophan present)
Study: 16961791
Drug: Tryptophan depletion
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan depletion condition (L-tryptophan omitted)
Study: 15242999
Drug: Laparoscopic electrocautery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic electrocautery of the ovaries followed by CC and recombinant FSH (rFSH)
Study: 8969629
Drug: Intravenous disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous disodium EDTA (3 g)
Study: 1534639
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine stored at 4 degrees C
Study: 1534639
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine heated for 1 week at 45 degrees C
Study: 1534639
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine heated for 1 month at 37 degrees C
Study: 3975851
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (doxorubicin, cyclophosphamide, and high-dose methotrexate)
Study: 3975851
Drug: Chemotherapy (among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (among entire cohort)
Study: 30865144
Drug: Another infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another infant physical therapy
Study: 28096005
Drug: Lullaby group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lullaby group (n=26) listened to male lullaby via headphones for 20 minutes daily over 3 days
Study: 9205924
Drug: Resorbable barrier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resorbable barrier in combination with decalcified freeze-dried bone allograft (DFDBA)
Study: 9205924
Drug: Non-smokers in
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-smokers in both treatment groups
Study: 3111785
Drug: Levonorgestrel 20
Normalized name: ethinyl estradiol-levonorgestrel 20 mcg-90 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 20 mcg/day IUD (LNg20)
Study: 26149244
Drug: Cabozantinib (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (140 mg/day, with dose modifications allowed)
Study: 24185158
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention to increase medication adherence
Study: 14700452
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release (SR)
Study: 14700452
Drug: Immediate-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulations
Study: 11202895
Drug: 5% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% chlorhexidine gel
Study: 1483292
Drug: Nafarelin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin and norethisterone 0.7 mg
Study: 1483292
Drug: Nafarelin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin and norethisterone 1.4 mg
Study: 1483292
Drug: Nafarelin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin and norethisterone 2.45 mg
Study: 2996342
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (hydrochlorothiazide, timolol, and hydralazine)
Study: 22247480
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (3 ng/kg per minute for 1 hour) in patients with POTS
Study: 20193079
Drug: GSK256066 87.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256066 87.5 mcg once per day
Study: 18095949
Drug: Tissue angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue angiotensin-converting enzyme (ACE) inhibitors
Study: 12823383
Drug: Lifestyle and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle and behavioural interventions (e.g., education about the prostate and bladder, avoiding caffeine, urethral milking, reassurance about prostate cancer)
Study: 11324900
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1 mg per day
Study: 8467027
Drug: endotracheally administered
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: endotracheally administered tobramycin
Study: 2870533
Drug: dihomo‐gammalinolenic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihomo‐gammalinolenic acid (DHLA) with depot neuroleptic medication
Study: 2870533
Drug: placebo depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo depot medication and DHLA capsules
Study: 2870533
Drug: placebo depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo depot medication and placebo capsules